These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19690030)

  • 1. Imaging of proliferation in hepatocellular carcinoma with the in vivo marker 18F-fluorothymidine.
    Eckel F; Herrmann K; Schmidt S; Hillerer C; Wieder HA; Krause BJ; Schuster T; Langer R; Wester HJ; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2009 Sep; 50(9):1441-7. PubMed ID: 19690030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors.
    Herrmann K; Eckel F; Schmidt S; Scheidhauer K; Krause BJ; Kleeff J; Schuster T; Wester HJ; Friess H; Schmid RM; Schwaiger M; Buck AK
    J Nucl Med; 2008 Sep; 49(9):1437-44. PubMed ID: 18703612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.
    Thureau S; Chaumet-Riffaud P; Modzelewski R; Fernandez P; Tessonnier L; Vervueren L; Cachin F; Berriolo-Riedinger A; Olivier P; Kolesnikov-Gauthier H; Blagosklonov O; Bridji B; Devillers A; Collombier L; Courbon F; Gremillet E; Houzard C; Caignon JM; Roux J; Aide N; Brenot-Rossi I; Doyeux K; Dubray B; Vera P
    J Nucl Med; 2013 Sep; 54(9):1543-50. PubMed ID: 23918733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG.
    Buck AK; Halter G; Schirrmeister H; Kotzerke J; Wurziger I; Glatting G; Mattfeldt T; Neumaier B; Reske SN; Hetzel M
    J Nucl Med; 2003 Sep; 44(9):1426-31. PubMed ID: 12960187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
    Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
    J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors.
    Jacobs AH; Thomas A; Kracht LW; Li H; Dittmar C; Garlip G; Galldiks N; Klein JC; Sobesky J; Hilker R; Vollmar S; Herholz K; Wienhard K; Heiss WD
    J Nucl Med; 2005 Dec; 46(12):1948-58. PubMed ID: 16330557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive value of initial 18F-FLT uptake in patients with aggressive non-Hodgkin lymphoma receiving R-CHOP treatment.
    Herrmann K; Buck AK; Schuster T; Junger A; Wieder HA; Graf N; Ringshausen I; Rudelius M; Wester HJ; Schwaiger M; Keller U; Dechow T
    J Nucl Med; 2011 May; 52(5):690-6. PubMed ID: 21498532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular imaging of proliferation in malignant lymphoma.
    Buck AK; Bommer M; Stilgenbauer S; Juweid M; Glatting G; Schirrmeister H; Mattfeldt T; Tepsic D; Bunjes D; Mottaghy FM; Krause BJ; Neumaier B; Döhner H; Möller P; Reske SN
    Cancer Res; 2006 Nov; 66(22):11055-61. PubMed ID: 17108145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging bone and soft tissue tumors with the proliferation marker [18F]fluorodeoxythymidine.
    Buck AK; Herrmann K; Büschenfelde CM; Juweid ME; Bischoff M; Glatting G; Weirich G; Möller P; Wester HJ; Scheidhauer K; Dechow T; Peschel C; Schwaiger M; Reske SN
    Clin Cancer Res; 2008 May; 14(10):2970-7. PubMed ID: 18445694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models: a comparison with 18F-FDG and 18F-FLT.
    Zhao S; Kuge Y; Kohanawa M; Takahashi T; Zhao Y; Yi M; Kanegae K; Seki K; Tamaki N
    J Nucl Med; 2008 Jan; 49(1):135-41. PubMed ID: 18077525
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 18F-FLT PET and 18F-FDG PET in esophageal cancer.
    van Westreenen HL; Cobben DC; Jager PL; van Dullemen HM; Wesseling J; Elsinga PH; Plukker JT
    J Nucl Med; 2005 Mar; 46(3):400-4. PubMed ID: 15750150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring Response to Transarterial Chemoembolization in Hepatocellular Carcinoma Using
    Sharma R; Inglese M; Dubash S; Lu H; Pinato DJ; Sanghera C; Patel N; Chung A; Tait PD; Mauri F; Crum WR; Barwick TD; Aboagye EO
    J Nucl Med; 2020 Dec; 61(12):1743-1748. PubMed ID: 32513905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging gastric cancer with PET and the radiotracers 18F-FLT and 18F-FDG: a comparative analysis.
    Herrmann K; Ott K; Buck AK; Lordick F; Wilhelm D; Souvatzoglou M; Becker K; Schuster T; Wester HJ; Siewert JR; Schwaiger M; Krause BJ
    J Nucl Med; 2007 Dec; 48(12):1945-50. PubMed ID: 18006614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (4S)-4-(3-18F-fluoropropyl)-L-glutamate for imaging of xC transporter activity in hepatocellular carcinoma using PET: preclinical and exploratory clinical studies.
    Baek S; Mueller A; Lim YS; Lee HC; Lee YJ; Gong G; Kim JS; Ryu JS; Oh SJ; Lee SJ; Bacher-Stier C; Fels L; Koglin N; Schatz CA; Dinkelborg LM; Moon DH
    J Nucl Med; 2013 Jan; 54(1):117-23. PubMed ID: 23232273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [18F]3'-deoxy-3'-fluorothymidine PET for the diagnosis and grading of brain tumors.
    Choi SJ; Kim JS; Kim JH; Oh SJ; Lee JG; Kim CJ; Ra YS; Yeo JS; Ryu JS; Moon DH
    Eur J Nucl Med Mol Imaging; 2005 Jun; 32(6):653-9. PubMed ID: 15711980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic usefulness of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography in recurrent brain tumor.
    Hong IK; Kim JH; Ra YS; Kwon DH; Oh SJ; Kim JS
    J Comput Assist Tomogr; 2011; 35(6):679-84. PubMed ID: 22082535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Kinetic analysis of 3'-deoxy-3'-fluorothymidine PET studies: validation studies in patients with lung cancer.
    Muzi M; Vesselle H; Grierson JR; Mankoff DA; Schmidt RA; Peterson L; Wells JM; Krohn KA
    J Nucl Med; 2005 Feb; 46(2):274-82. PubMed ID: 15695787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo validation of 3'deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors.
    Vesselle H; Grierson J; Muzi M; Pugsley JM; Schmidt RA; Rabinowitz P; Peterson LM; Vallières E; Wood DE
    Clin Cancer Res; 2002 Nov; 8(11):3315-23. PubMed ID: 12429617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.